The basis of platelets: Platelets and atherothrombosis: An understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients

Drugs

Volumn 70, Issue SUPPL. 1, 2010, Pages 9-14

  Drouet, Ludovic ^a   Bal Dit Sollier, Claire ^a   Henry, Patrick ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PROSTAGLANDIN SYNTHASE; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; THROMBOXANE A2;

ACETYLATION; ARTERY DISEASE; ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; JAPAN; LOW DRUG DOSE; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UNITED KINGDOM; CLINICAL TRIAL (TOPIC); DRUG EFFECT; METABOLISM; NOMENCLATURE; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

ABBREVIATIONS AS TOPIC; ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS;

EID: 78049233766     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00000005-000000000-00000     Document Type: Review

References (12)

1. Lechat P, Priollet P. Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role? J Mal Vasc 2006; 31: 129-34
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
3. Cubbon RM, Gale CP, Rajwani A, et al. Aspirin and mortality in patients with diabetes sustaining acute coro¬nary syndrome. Diabetes Care. 2008; 31: 363-5
4. van der Zee PM, Biró E, Ko Y, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-64
5. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program. 2007: 114-20
6. Sideris G, Guyetand S, Belluci A, et al. Low dose aspirin does not maintain a 24-hour biological efcacy in type-2 diabetic patients. Eur Heart J 2007; 28 (suppl 1): 267
7. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
8. Belch J, Maccuish A, Cmpbell I, et al. The prevention of progression of arterial disease and diabetes (POPA-DAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
9. Fowkes G. Aspirin for asymptomatic atherosclerosis (AAA) study. Presented at ESC congress 2009
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996; 348:1329-39
11. Bhatt DL, Marso SP, Hirsch AT, et al. Amplifed bene-ft of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8
12. Bal Dit Sollier C, Bergen N, Boval B, et al. Functional variability of platelet response to clopidogrel correlates with P2Y (12) receptor occupancy. Thromb Haemost 2009; 101: 116-22